Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
2740(c) 2816(c) 2798(c) 2827(c) 2780 Last
142 220 157 092 104 501 99 142 88 714 Volume
+1.48% +2.77% -0.64% +1.04% -1.66% Change
More quotes
Estimated financial data (e)
Sales 2021 8 024 M 1 264 M 1 264 M
Net income 2021 2 223 M 350 M 350 M
Net cash position 2021 15 352 M 2 418 M 2 418 M
P/E ratio 2021 85,3x
Yield 2021 -
Sales 2022 10 572 M 1 665 M 1 665 M
Net income 2022 3 420 M 539 M 539 M
Net cash position 2022 18 308 M 2 884 M 2 884 M
P/E ratio 2022 52,9x
Yield 2022 -
Capitalization 185 B 29 111 M 29 115 M
EV / Sales 2021 21,1x
EV / Sales 2022 15,8x
Nbr of Employees 1 029
Free-Float 94,9%
More Financials
Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the... 
Sector
Biotechnology & Medical Research
Calendar
11/03 | 11:00amEarnings Release
More about the company
Ratings of Genmab A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GENMAB A/S
09/22GENMAB A/S : (English translation of Articles of Association) (Form 6-K)
PU
09/22GENMAB A/S : Articles of association dated September 21, 2021 – English
PU
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/22GENMAB A/S : Investor Presentation - September 2021
PU
09/21GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise (Form 6-K..
PU
09/21Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
09/21SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
AQ
09/21SEAGEN : Genmab Win Accelerated US FDA Nod For Cervical Cancer Drug
MT
09/20GENMAB A/S : TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor,..
PU
09/20SEAGEN : Genmab Win US FDA Accelerated Approval of Tivdak in Previously Treated Recurrent,..
MT
09/20GENMAB A/S : and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab ved..
AQ
09/20PRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
09/20SEAGEN : Genmab's Cervical Cancer Combos Show Anti-Tumor Activity In Phase I Study
MT
09/19GENMAB A/S : and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab ..
AQ
09/19GENMAB A/S : Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tis..
BU
More news
News in other languages on GENMAB A/S
09/22GlobeNewswire/Pfizer und BioNTech erweitern -3-
09/20Seagen et Genmab obtiennent l'autorisation accélérée de la FDA pour le Tivdak dans le t..
09/20GlobeNewswire/Pfizer und BioNTech geben positive -4-
09/18GlobeNewswire/FDA-Beratungsausschuss unterstützt -4-
09/16AVIS D'ANALYSTES DU JOUR : Air France KLM, Eurofins, Infineon, Idorsia, Ab Inbev, Getlink,..
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 827,00 DKK
Average target price 2 765,22 DKK
Spread / Average Target -2,19%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S14.78%29 177
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.33.88%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018